Work Here?
Overview
iLoF combines artificial intelligence with photonics to speed up personalized drug discovery by turning light signals from small, non-invasive blood samples into optical fingerprints stored in a cloud library. The platform collects light signals, creates fingerprints, uploads them to the cloud, and uses AI to extract data and identify biomarkers to guide patient stratification for trials. It differentiates itself by linking non-invasive optical fingerprints with a cloud-based data library and offering a data-access subscription and end-to-end service for pharma, enabling scalable biomarker discovery and patient grouping. Its goal is to shorten drug development timelines and trial screening costs by providing AI-driven, non-invasive biomarker insights for more patient-centric studies.
About iLoF
Industries
Data & Analytics
AI & Machine Learning
Biotechnology
Healthcare
Company Size
11-50
Company Stage
Early VC
Total Funding
$13M
Headquarters
London, United Kingdom
Founded
2019
Get referred to iLoF
See people who can refer or advise you
Simplify's Take
What believers are saying
- March 2026 Bluepharma collaboration broadens commercialization beyond Alzheimer’s into manufacturing and R&D.
- 2025 revenue grew over 40%, showing real adoption momentum.
- The March 2026 Bio-Hermes-002 contract across 30-plus sites expands dataset depth and referrals.
What critics are saying
- iLoF still depends on research contracts; March 2026 Bluepharma does not prove durable demand.
- A $200,000 March 2026 SAFE signals tiny financing relative to platform commercialization needs.
- If Optomics fails clinical validation, iLoF becomes a niche services vendor and funding dries up.
What makes iLoF unique
- Optomics combines photonics and AI for non-invasive patient stratification in complex diseases.
- iLoF has credibility with AstraZeneca, Johnson & Johnson, Hamamatsu, and Bluepharma.
- Bio-Hermes-002 deployment anchors iLoF inside a major Alzheimer’s research network.
Help us improve and share your feedback! Did you find this helpful?
Funding
Total Funding
$13M
Above
Industry Average
Funded Over
8 Rounds
Benefits
Health Insurance
Flexible Work Hours
Remote Work Options
Company Social Events
Performance Bonus
Stock Options
Growth & Insights and Company News
6 month growth
↑ 13%1 year growth
↑ 10%2 year growth
↑ 5%Bulgarian venture capital firm Webit Investment Network has invested €200,000 in UK-based deeptech company iLoF through a simple agreement for future equity instrument. The investment joins existing backers including Microsoft Ventures, Lunar Ventures, Quiet Capital, Hamamatsu and EIT Health. iLoF develops a deeptech platform combining photonics and AI to analyse biological samples, creating molecular fingerprints for pre-clinical analytics, biopharma and clinical applications. The company works with AstraZeneca, Johnson & Johnson and Hamamatsu Medical Centers, with revenues growing over 40% in 2025 versus 2024. The investment expands Webit's healthcare and biotechnology vertical and complements its existing position in French medical device company InHeart.
iLoF, a company pioneering Optomics, an AI-powered photonics platform for drug development, has announced a strategic collaboration with Portuguese pharmaceutical firm Bluepharma. The partnership will integrate Optomics across the pharmaceutical value chain, exploring opportunities in drug development, research and manufacturing. Under the agreement, Optomics will be deployed in real-world settings to evaluate the platform against regulatory and quality standards. The collaboration aims to enhance Bluepharma's capability to develop complex formulations with greater speed and accuracy whilst addressing critical bottlenecks in drug development processes. The announcement follows iLoF's recent $1.5 million clinical research contract to deploy Optomics across over 30 Alzheimer's disease study sites in the US, Canada and UK, and a strategic partnership with Hamamatsu Photonics Japan.
A million each for iLoF and Restorative Neurotechnologies
Editor’s Note: This post has been created in collaboration and with financial support from EIT Jumpstarter as a Media Partner. If you’re also interested in partnering with us, just reach out. The EIT Jumpstarter Grand Final event is a pre-accelerator programme that helps European innovators and entrepreneurs build a viable business model around their innovative idea. We got an inside look at the programme from Dora Marosvolgyi, the woman leading the EIT Community’s Strategic Innovation Projects
To develop "effective therapies for millions of patients around the world", iLof will need to hire 20 more people by 2023 and is looking for profiles in physics, data science, biology and product management.
iLoF is Hiring for 2 Jobs on Simplify!
Find jobs on Simplify and start your career today
About iLoF
Industries
Data & Analytics
AI & Machine Learning
Biotechnology
Healthcare
Company Size
11-50
Company Stage
Early VC
Total Funding
$13M
Headquarters
London, United Kingdom
Founded
2019
iLoF is Hiring for 2 Jobs on Simplify!
Find jobs on Simplify and start your career today